However, there is evidence that SAA promotes insulin resistance [25] and that intensive insulin therapy can reduce SAA levels [4], whilst the insulin-sensitising and antioxidant drug troglitazone is reported to lower SAA in T2DM subjects [26]. The gene discussed is INS; the disease is type 2 diabetes mellitus.